Please login to the form below

Not currently logged in
Email:
Password:

cladribine

This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.

Sanofi licences Principia MS drug in $805m deal

Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.

Latest news

  • Merck mulls sale of consumer health division Merck mulls sale of consumer health division

    The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of

  • Merck gets CHMP backing for long-delayed oral MS drug Merck gets CHMP backing for long-delayed oral MS drug

    Follow-up studies also revealed that oral cladribine could be stopped in year three and four without an increase in relapses. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.

  • Avelumab costs peg back profit at Merck KGaA Avelumab costs peg back profit at Merck KGaA

    Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of  evofosfamide  in advanced soft tissue

  • Merck's pharma unit faces tougher 2017 as fertility boost recedes Merck's pharma unit faces tougher 2017 as fertility boost recedes

    Top of that list is oral MS therapy cladribine, which was submitted for approval in the EU in June, and according to Kuhnert is proceeding through regulatory review as expected.

  • Merck sees €2bn from new launches by 2022 Merck sees €2bn from new launches by 2022

    Other than avelumab, Merck has just two other candidates in late-stage development, namely oral cladribine for multiple sclerosis (MS) and a biosimilar of AbbVie's TNF inhibitor Humira (adalimumab). ... Cladribine is closest to market having already been

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics